The International Consensus Classification of acute myeloid leukemia

Weinberg, Olga K.; Porwit, Anna; Orazi, Attilio; Foucar, Kathryn; Duncavage, Eric J.; Arber, Daniel A.

doi:10.1007/s00428-022-03430-4

Cited by 41 publications

(50 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, distinct separation MDS from AML is no longer optimal [32]. As a result, both WHO-5 and ICC stress that MDS with 10–19% blasts and no defining genetic abnormalities (MDS-IB2 in WHO-5 and MDS/AML in ICC) can be treated as either MDS or AML to optimize the clinical outcomes of this group [1 ▪▪ ,33,34 ▪ ].…”

Section: Myeloid Precursor Lesions and Myelodysplastic Syndromesmentioning

confidence: 99%

“…Hematologic neoplasms with germline predisposition (HNGP) includes MDS, MPN, MDS/MPN, AML, and lymphoid neoplasms such as non-Hodgkin lymphoma and ALL/LBL [1 ▪▪ ,3 ▪▪ ,34 ▪ ] (Supplementary Table 1, http://links.lww.com/COH/A27). HNGP is quite common, and germline predisposition variants may cause cancers at any age.…”

Section: Hematologic Neoplasms With Germline Predispositionmentioning

confidence: 99%

“…WHO-5 and ICC define AML categories by cytogenetic abnormalities, mutational profiles, and patient's history (Supplementary Table 1, http://links.lww.com/COH/A27) [1 ▪▪ ,3 ▪▪ ,33,34 ▪ ]. Both WHO-5 and ICC move to a more genetically defined AML classification because of the rapid evolution of our understanding of the molecular landscape of AML.…”

Section: Acute Myeloid Leukemiamentioning

confidence: 99%

“…WHO-5 and ICC emphasize the genetic features rather than an arbitrary blast cut-off to define AML [1 ▪▪ ,3 ▪▪ ,33,34 ▪ ]. Both classifications eliminate the cut-off of 20% blasts for AML with defining genetic abnormalities with two exceptions, AML with BCR::ABL1 fusion (WHO-5 and ICC) and AML with CEBPA mutation (WHO-5) [3 ▪▪ ,44]; however, ICC mandates a cut-off of 10% blasts.…”

Section: Acute Myeloid Leukemiamentioning

confidence: 99%

“…In both WHO-5 and ICC, the significance of underlying molecular genetic abnormalities exceeds immunophenotype alone in acute leukemia. Indeed, recent universal BCL11B rearrangements across mixed phenotype acute leukemia (MPAL) with T/myeloid features, early T-cell precursor ALL, acute leukemia of ambiguous lineage (ALAL), and a minor subset of AML with minimal differentiation imply the biologic continuum [1 ▪▪ ,34 ▪ ]. Moreover, with the new category of AML with myelodysplasia-related genetic changes , many previously MPAL with predominant myeloblast populations are now assigned as AML based on specific cytogenetic abnormalities or gene mutations [57–61].…”

Section: Acute Myeloid Leukemiamentioning

confidence: 99%

See 4 more Smart Citations

The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications

Zheng

Zhang

Pan

2022

Current Opinion in Hematology

View full text Add to dashboard Cite

Purpose of reviewThere have been major advances in our understanding of molecular pathogenesis of myeloid neoplasms, which prompt the updates in the classification of myeloid neoplasms in the fifth edition of World Health Organization Classification (WHO-5) and the new International Consensus Classification (ICC). The purpose of this review is to provide an overview of these two classification systems for myeloid neoplasms.Recent findingsThe definition, classification, and diagnostic criteria in many myeloid entities have been refined in WHO-5 and ICC with improved understanding of morphology and integration of new genetic findings. Particularly, molecular and cytogenetic studies have been increasingly incorporated into the classification, risk stratification, and selection of therapy of myeloid neoplasms. Overall, despite some revisions and discrepancies between WHO-5 and ICC, the major categories of myeloid neoplasms remain the same. Further validation studies are warranted to fine-tune and, ideally, integrate these two classifications.SummaryIntegration of clinical information, laboratory parameters, morphologic features, and cytogenetic and molecular studies is essential for the classification of myeloid neoplasms, as recommended by both WHO-5 and ICC.

show abstract

Section: Myeloid Precursor Lesions and Myelodysplastic Syndromesmentioning

confidence: 99%

Section: Hematologic Neoplasms With Germline Predispositionmentioning

confidence: 99%

Section: Acute Myeloid Leukemiamentioning

confidence: 99%

Section: Acute Myeloid Leukemiamentioning

confidence: 99%

Section: Acute Myeloid Leukemiamentioning

confidence: 99%

See 3 more Smart Citations

The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications

Zheng

Zhang

Pan

2022

Current Opinion in Hematology

View full text Add to dashboard Cite

show abstract

Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia

Arber

Orazi

2022

American J Hematol

View full text Add to dashboard Cite

The increase in our understanding of the genetic complexity of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well at the rapid introduction of more targeted therapies for these diseases has made the diagnosis and classification of AML and MDS more challenging and nuanced. The third, fourth, and revised fourth edition World Health Organization (WHO) classifications, published by the International Agency on Cancer (IARC), have succeeded in incorporating new genetic criteria in the various disease classification schemes by carefully handling the overwhelming amount of data and complexity of these disorders. Updating an existing classification system requires not only integrating the most recent published literature, but also developing a consensus by overcoming differences of opinion on how to incorporate the new data. The updating process was developed by the Society for Hematopathology and the European Association for Hematopathology through a Clinical Advisory Committee (CAC). The CAC met prior to each classification being developed, to come to a consensus on what to change and how to incorporate those changes into comprehensive diagnostic criteria. IARC also provided input and published the classification within their Blue Book series.

show abstract

ICC‐2022 versus WHO‐2022 classification systems for acute leukemias and myeloid neoplasms: The perspective from two classical morphologists

Zini

Bennett

2023

American J Hematol

View full text Add to dashboard Cite

The International Consensus Classification of acute myeloid leukemia

Cited by 41 publications

References 72 publications

The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications

The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications

Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia

ICC‐2022 versus WHO‐2022 classification systems for acute leukemias and myeloid neoplasms: The perspective from two classical morphologists

Contact Info

Product

Resources

About